Clear Harbor Asset Management LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Clear Harbor Asset Management LLC purchased a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,500 shares of the company’s stock, valued at approximately $96,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ITOS. State Street Corp increased its position in iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after purchasing an additional 211,452 shares during the period. Clearline Capital LP bought a new position in shares of iTeos Therapeutics in the 2nd quarter valued at about $2,328,000. Algert Global LLC grew its position in shares of iTeos Therapeutics by 92.0% during the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after buying an additional 122,730 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after buying an additional 117,159 shares during the last quarter. Finally, Readystate Asset Management LP lifted its holdings in iTeos Therapeutics by 97.2% in the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock valued at $1,734,000 after buying an additional 83,700 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ITOS. Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, January 16th. Finally, Wells Fargo & Company cut their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th.

iTeos Therapeutics Stock Down 4.3 %

Shares of NASDAQ ITOS opened at $7.71 on Thursday. iTeos Therapeutics, Inc. has a twelve month low of $7.09 and a twelve month high of $18.75. The stock has a market cap of $281.65 million, a price-to-earnings ratio of -2.45 and a beta of 1.39. The company’s fifty day moving average is $7.94 and its 200-day moving average is $11.40.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.13. On average, research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.50% of the stock is owned by company insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.